E
Immunic, Inc. IMUX
$0.65 $0.00-0.31% NASDAQ
Recommendation
Prev Close
$0.65
Volume
1,356,365
Avg Vol (90D)
1,325,875
Market Cap
$78.43M
Dividend & Yield
--
52-Week Range
$0.56 - $1.40
P/E (TTM)
--
EPS (TTM)
-$0.94
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Immunic marks International Day of Persons with Disabilities with hope for MS sufferers
12/3/2025 - Proactive Investors - UK
B. Riley Forecasts Immunic's Q1 Earnings (NASDAQ:IMUX)
11/26/2025 - Ticker Report
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
11/26/2025 - GuruFocus
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
11/26/2025 - PR Newswire
Analysts Offer Predictions for Immunic FY2025 Earnings
11/24/2025 - MarketBeat
Equities Analysts Issue Forecasts for Immunic Q1 Earnings
11/21/2025 - MarketBeat
HC Wainwright Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00
11/15/2025 - MarketBeat
Immunic advances MS therapy vidofludimus calcium during Q3 - ICYMI
11/15/2025 - Proactive Investors - UK
Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS
11/14/2025 - MarketBeat
D. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00
11/14/2025 - MarketBeat
Immunic (NASDAQ:IMUX) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS
11/14/2025 - Ticker Report
Immunic price target lowered by $2 at H.C. Wainwright, here's why
11/14/2025 - The Fly
Immunic, Inc. Reports Q3 2025 Financial Results
11/14/2025 - TipRanks Financial Blog
Small cap wrap: Ideal Power, Immunic, Candel Therapeutics, Medicus Pharma, NEXE Innovations
11/13/2025 - Proactive Investors - UK
Immunic CEO on Q3 hightlighs, ECTRIMS 2025 and upcoming milestones
11/13/2025 - Proactive Investors - UK
Immunic CEO on Q3 highlights, ECTRIMS 2025 and upcoming milestones
11/13/2025 - Proactive Investors - UK
Immunic advances MS program with key clinical findings in Q3
11/13/2025 - Proactive Investors - UK
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/13/2025 - GuruFocus
Immunic (IMUX) Highlights Promising Clinical Advances in Multiple Sclerosis Trials
11/13/2025 - GuruFocus
Immunic reports Q3 EPS (13c), consensus (18c)
11/13/2025 - The Fly
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/13/2025 - PR Newswire
Q3 Earnings Forecast for Immunic Issued By Roth Capital
11/10/2025 - MarketBeat
Immunic (NASDAQ:IMUX) Coverage Initiated at Roth Capital
11/9/2025 - Ticker Report
Immunic CEO discusses MS focus, upcoming Phase 3 trial readouts - ICYMI
11/8/2025 - Proactive Investors - UK
Immunic (NASDAQ:IMUX) Now Covered by Analysts at Roth Capital
11/8/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$105.37M
EBIT (TTM)
-$105.53M
Net Income (TTM)
-$103.05M
Balance Sheet
Total Assets (Q)
$40.70M
Total Debt (Q)
$792.00K
Total Liabilities (Q)
$30.21M
Book Value Per Share (Q)
$0.1064
Cash Flow
Cash from Operations (TTM)
-$89.49M
Cash from Investing (TTM)
-$153.00K
Cash from Financing (TTM)
$65.60M
Net Change in Cash (TTM)
-$23.94M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
End of March (est)
Price History
Loading...
Beta
1.31
7-Day Total Return
-5.30%
30-Day Total Return
-20.95%
60-Day Total Return
-24.18%
90-Day Total Return
-39.81%
Year to Date Total Return
-36.27%
1-Year Total Return
-48.82%
2-Year Total Return
-44.92%
3-Year Total Return
-51.49%
5-Year Total Return
-96.38%
52-week Low
May 29, 2025 - $0.56
52-week High
Dec 03, 2024 - $1.40
Valuation
Market Cap
$78.43M - Micro Cap
Enterprise Value
$44.09M
Price/Sales (TTM)
--
Price/Book (Q)
6.13
Dividends and Shares
Shares Outstanding
193.90
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
imux.com
Phone Number
332 255 9818
Address
1200 Avenue of the Americas
New York, NY 10036
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed